Page last updated: 2024-09-02

deguelin and Leukemia

deguelin has been researched along with Leukemia in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Billi, AM; Bortul, R; Cappellini, A; Conte, R; Grafone, T; Mantovani, I; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL1
Chen, Y; Cui, G; Li, R; Shu, W; Wu, Q1

Other Studies

2 other study(ies) available for deguelin and Leukemia

ArticleYear
Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway.
    British journal of haematology, 2005, Volume: 129, Issue:5

    Topics: Acute Disease; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cells, Cultured; Cytarabine; Drug Resistance, Neoplasm; Erythropoietin; Etoposide; HL-60 Cells; Humans; Leukemia; Leukemia, Myeloid; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Rotenone; Signal Transduction; Stem Cell Factor; Stem Cells

2005
Deguelin represses both the expression of nucleophosmin and some nucleoporins: Nup88 and Nup214 in Jurkat cells.
    Biological & pharmaceutical bulletin, 2008, Volume: 31, Issue:1

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Humans; Jurkat Cells; Leukemia; Nuclear Pore Complex Proteins; Rotenone

2008